oslo
(4)
sensiBel
sensiBel is a Norwegian semiconductor company that makes optical MEMS microphones - tiny chip-scale devices that use a laser and photodetector to sense a diaphragm's motion instead of the electrical (capacitive) method used in almost every microphone for the past century. Its flagship SBM100B is billed as the world's first production optical MEMS microphone, delivering studio-grade specs (80 dBA SNR, 146 dB acoustic overload point, 132 dB dynamic range) in a package small enough for earbuds, laptops and microphone arrays. Spun out of Norwegian research institute SINTEF in 2017, sensiBel sells to audio, consumer-electronics and pro-audio manufacturers and counts Sennheiser among its investors.
Huddly
Huddly is an Oslo-based company that builds AI-powered conference cameras for hybrid meeting rooms. By running computer-vision neural networks directly on the camera (edge AI), Huddly devices automatically frame speakers, switch angles like a TV director, and improve over time through software updates. Its products work with Microsoft Teams, Zoom and Google Meet, and range from the single wide-angle IQ to the L1 and S1 and the multi-camera Huddly Crew system marketed as the world's first AI director. Founded in 2013, Huddly listed on Euronext Growth Oslo in December 2023.
Tana
Tana is an AI-native workspace that turns messy notes, meetings and voice memos into structured, queryable knowledge. Its signature feature, Supertags, lets any bullet point become a database record with defined fields, so notes double as a living knowledge graph that AI agents can read, summarize and act on. Founded in 2021 by ex-Googlers and productivity builders and based in Palo Alto with an engineering hub in Oslo, Tana raised a $14M Series A in February 2025 (led by Tola Capital), reaching $25M total funding after emerging from a stealth beta with a 160,000+ person waitlist.
Calluna Pharma
Calluna Pharma is an Oslo-based clinical-stage biotech building first-in-class antibodies that switch off the upstream signals driving inflammation and fibrosis. Formed in 2024 from the merger of Oxitope Pharma and Arxx Therapeutics and backed by a EUR 75 million Series A, the company targets damage-associated molecular patterns (DAMPs) such as S100A4 to halt diseases like idiopathic pulmonary fibrosis at their root rather than managing symptoms.